Ftse Mib
33.787,00
0,00%
DAX
19.999,47
0,00%
S&P 500
5.867,08
-0,09%
NASDAQ
19.372,77
-0,10%
Bitcoin
97.605,97
0,15%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ BioCryst Pharmaceuticals Inc (BCRX) BioCryst Pharmaceuticals Inc (BCRX) Notizie

BCRX

BioCryst Pharmaceuticals (BCRX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BCRX
DataOraFonteTitoloSimboloCompagnia
17/12/202422:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
13/12/202422:23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
04/12/202422:15GlobeNewswire Inc.BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
18/11/202408:00GlobeNewswire Inc.BioCryst Launches ORLADEYO® (berotralstat) in IrelandNASDAQ:BCRXBioCryst Pharmaceuticals Inc
06/11/202413:00GlobeNewswire Inc.BioCryst to Present at Upcoming Investor ConferencesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
05/11/202423:19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BCRXBioCryst Pharmaceuticals Inc
04/11/202413:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BCRXBioCryst Pharmaceuticals Inc
04/11/202413:00GlobeNewswire Inc.BioCryst Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:BCRXBioCryst Pharmaceuticals Inc
24/10/202414:00GlobeNewswire Inc.BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
21/10/202413:00GlobeNewswire Inc.BioCryst to Report Third Quarter 2024 Financial Results on November 4NASDAQ:BCRXBioCryst Pharmaceuticals Inc
14/10/202413:00GlobeNewswire Inc.BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
10/10/202413:00GlobeNewswire Inc.BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific MeetingNASDAQ:BCRXBioCryst Pharmaceuticals Inc
02/10/202413:00GlobeNewswire Inc.BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton SyndromeNASDAQ:BCRXBioCryst Pharmaceuticals Inc
30/09/202413:00GlobeNewswire Inc.U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National StockpileNASDAQ:BCRXBioCryst Pharmaceuticals Inc
17/09/202413:00GlobeNewswire Inc.BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema AttacksNASDAQ:BCRXBioCryst Pharmaceuticals Inc
10/09/202418:09Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:BCRXBioCryst Pharmaceuticals Inc
06/09/202408:00GlobeNewswire Inc.BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin SymposiumNASDAQ:BCRXBioCryst Pharmaceuticals Inc
05/09/202413:00GlobeNewswire Inc.BioCryst Appoints Dr. Donald Fong Chief Medical OfficerNASDAQ:BCRXBioCryst Pharmaceuticals Inc
06/08/202422:38Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BCRXBioCryst Pharmaceuticals Inc
05/08/202413:00GlobeNewswire Inc.BioCryst Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:BCRXBioCryst Pharmaceuticals Inc
05/08/202411:46IH Market NewsU.S. Index Futures and Oil Prices Plunge on Recession ConcernsNASDAQ:BCRXBioCryst Pharmaceuticals Inc
22/07/202413:00GlobeNewswire Inc.BioCryst to Report Second Quarter 2024 Financial Results on August 5NASDAQ:BCRXBioCryst Pharmaceuticals Inc
02/06/202410:00GlobeNewswire Inc.BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) TreatmentNASDAQ:BCRXBioCryst Pharmaceuticals Inc
14/05/202413:00GlobeNewswire Inc.BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical ImmunologyNASDAQ:BCRXBioCryst Pharmaceuticals Inc
13/05/202413:00GlobeNewswire Inc.ORLADEYO® (berotralstat) Approved in MexicoNASDAQ:BCRXBioCryst Pharmaceuticals Inc
09/05/202413:00GlobeNewswire Inc.BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
06/05/202413:00GlobeNewswire Inc.BioCryst Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:BCRXBioCryst Pharmaceuticals Inc
22/04/202413:00GlobeNewswire Inc.BioCryst to Report First Quarter 2024 Financial Results on May 6NASDAQ:BCRXBioCryst Pharmaceuticals Inc
17/04/202410:30GlobeNewswire Inc.BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory AgencyNASDAQ:BCRXBioCryst Pharmaceuticals Inc
27/02/202423:05Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:BCRXBioCryst Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BCRX

La tua Cronologia

LSE
10CR
Hsbc Bk. 23
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network